Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer

被引:28
作者
Mueller, Christine M. [1 ]
Mai, Phuong L. [1 ]
Bucher, Jaime [2 ]
Peters, June A. [1 ]
Loud, Jennifer T. [1 ]
Greene, Mark H. [1 ]
机构
[1] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[2] Univ Toledo, Coll Med, Toledo, OH 43606 USA
来源
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2008年 / 8卷 / 1期
关键词
D O I
10.1186/1472-6882-8-17
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Complementary and alternative medicine (CAM) use is well documented among breast cancer patients and survivors, but little evidence is available to describe rates and patterns of use among women at increased genetic risk of breast cancer. Methods: A pre-visit telephone interview was conducted to ascertain CAM use among the BRCA mutation carriers enrolled in a high-risk breast cancer screening study. Participants were asked to report on their use of thirteen therapies within the year prior to enrollment into the study. Logistic regression was used to evaluate the association between various factors and CAM use in this population. Results: Among the 164 BRCA1 or BRCA2 mutation-positive (BRCA+) women in this analysis, 78% reported CAM use, with prayer and lifestyle diet being the two most commonly reported modalities. Many subjects used multiple CAM therapies, with 34% reporting use of three or more modalities. The most commonly used modalities were mind-body therapies and biologically-based practices, 61.6% and 51.8%, respectively. High-risk women were more likely to use CAM if they were older, more educated, more worried about ovarian cancer risk, or had a previous cancer diagnosis. Conclusion: This study suggests that the prevalence of CAM use is high among BRCA mutation carriers, with frequency of use comparable to that of breast cancer patients and survivors. Given the high prevalence of CAM use in our subjects, especially biologically-based therapies including herbal supplements, whose safety and efficacy in relation to cancer risk are unknown, our study suggests that future research is necessary to clarify these risks, and that it is important for providers to inquire about and to discuss the pros and cons of CAM use with their BRCA+ patients.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians [J].
Ashikaga, T ;
Bosompra, K ;
O'Brien, P ;
Nelson, L .
SUPPORTIVE CARE IN CANCER, 2002, 10 (07) :542-548
[2]  
Astin John A, 2006, J Soc Integr Oncol, V4, P157, DOI 10.2310/7200.2006.019
[3]  
Barnes Patricia M, 2004, Adv Data, P1
[4]  
Bono Christine, 2007, Res Social Adm Pharm, V3, P1, DOI 10.1016/j.sapharm.2006.04.001
[5]   Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005 [J].
Boon H.S. ;
Olatunde F. ;
Zick S.M. .
BMC Women's Health, 7 (1)
[6]   Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations [J].
DiGianni, LM ;
Rue, M ;
Emmons, K ;
Garber, JE .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (01) :70-75
[7]  
DiGianni LM, 2003, CANCER EPIDEM BIOMAR, V12, P321
[8]   Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey [J].
Eisenberg, DM ;
Davis, RB ;
Ettner, SL ;
Appel, S ;
Wilkey, S ;
van Rompay, M ;
Kessler, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18) :1569-1575
[9]  
Emmons KM, 2000, CANCER EPIDEM BIOMAR, V9, P89
[10]   Prevalence and treatment of menopausal symptoms among breast cancer survivors [J].
Harris, PF ;
Remington, PL ;
Trentham-Dietz, A ;
Allen, CI ;
Newcomb, PA .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (06) :501-509